A new generation of proteasome inhibitors, immunomodulatory agents, and deacetylase inhibitors are currently being investigated in clinical trials to treat patients with relapsed or refractory multiple myeloma.
Michael Marlan Mohundro, PharmD
Advertisement
Articles by Michael Marlan Mohundro, PharmD
Advertisement
Latest Updated Articles
On the Horizon for Multiple Myeloma: Update on Novel Agents, Bone TherapiesSeptember 12th 2012
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer
2
Firmonertinib Fails to Meet PFS End Point in First-Line EGFR Exon 20 Insertion–Mutant NSCLC
3
Carotuximab Plus Apalutamide Improves PFS in mCRPC
4
Dr Dhakal on the Investigation of Novel CAR T-Cell Therapy Approaches in Myeloma
5